News tagged with myelofibrosis
Related topics: blood cancer , bone marrow
Myelofibrosis
Myelofibrosis, also known as myeloid metaplasia, chronic idiopathic myelofibrosis, osteomyelofibrosis and primary myelofibrosis is a disorder of the bone marrow. It is currently classified as a myeloproliferative disease in which the proliferation of an abnormal type of bone marrow stem cell results in fibrosis, or the replacement of the marrow with collagenous connective tissue fibers.
This text uses material from Wikipedia and is available under the GNU Free Documentation License.
Britain snubs costly Novartis blood cancer drug
British health authorities said on Wednesday they would not recommend Jakavi, a drug produced by Swiss pharmaceutical company Novartis to treat a rare form of blood cancer, deeming it too expensive.
Medications
Feb 13, 2013 |
not rated yet |
0
How the tilt of a cell-surface receptor prevents cancer
Clear communication between cells is essential to every aspect of the body's internal function. But since cells can't talk, or send emails, how do they communicate?
Cancer
Jan 31, 2013 |
5 / 5 (1) |
0
|
Combination therapy using JAK2 and HSP90 inhibitors increased efficacy in myelofibrosis in vivo
Researchers have demonstrated that combination therapy with PU-H71 and ruxolitinib increases the durability and effectiveness of a treatment that had previously shown limited utility for patients with myelofibrosis.
Cancer
Dec 09, 2012 |
not rated yet |
0
Novel therapeutic agents provide hope for patients with hard-to-treat blood disorders
Encouraging safety and efficacy data on novel and emerging therapies presented at the 54th Annual Meeting of the American Society of Hematology (ASH) signal an important step forward in the development of treatment strategies ...
Cancer
Dec 09, 2012 |
not rated yet |
0
EU approves Novartis-Incyte blood cancer drug
Novartis AG and Incyte Corp. said Tuesday that European Union regulators approved their blood cancer drug Jakavi.
Medications
Sep 04, 2012 |
not rated yet |
0
Improved survival for patients with chronic blood diseases
(Medical Xpress) -- New research from Karolinska Institutet shows that the survival for patients with chronic myeloproliferative diseases has improved in recent decades. This is despite the fact that no targeted drugs have ...
Cancer
Jul 17, 2012 |
not rated yet |
0
Drug offers relief for symptoms of myelofibrosis
People with a blood cancer — myelofibrosis — can benefit from a drug called ruxolitinib, according to a randomized, double-blind, placebo-controlled clinical trial that included patients and researchers from the ...
Cancer
Feb 29, 2012 |
not rated yet |
0
|
Ruxolinitib better at reducing myelofibrosis symptoms, study shows
In a major advance in treatment, a multicenter study found that ruxolinitib did a better job than off-label chemotherapy drugs reducing the terrible symptoms associated with myelofibrosis, including pain, enlarged spleen, anemia, fever, chills ...
Cancer
Dec 12, 2011 |
not rated yet |
0
FDA approves first drug for bone marrow disorder
The first drug to treat a rare disorder that causes red blood cells to build up inside bone marrow was cleared Wednesday by the Food and Drug Administration
Medications
Nov 16, 2011 |
not rated yet |
0
New study identifies new potential approaches to treat myelofibrosis
(Medical Xpress) -- A new study conducted by a team of researchers at Boston University School of Medicine (BUSM) sheds light on a possible new approach to treat the bone marrow disease known as myelofibrosis by inhibiting ...
Medical research
Jun 23, 2011 |
not rated yet |
0
